We report a case of agranulocytosis caused by ethambutol in a 79-year-old man with pulmonary tuberculosis. He was referred for fever and skin rash developed on 21th day after antituberculosis drugs (isoniazid, rifampicin, ethambutol, and pyrazinamide) intake. Complete blood count at the time of diagnosis of pulmonary tuberculosis was normal. On the seventh admission day, agranulocytosis was developed with absolute neutrophil count of 70/μL. We discontinued all antituberculosis drugs, and then treated with granulocyte colony-stimulating factor. Three days later, the number of white blood cell returned to normal. We administered isoniazid, pyrazinamide, and ethambutol in order with an interval. However, fever and skin rash developed again when adding ethambutol, so we discontinued ethambutol. After these symptoms disappeared, we added rifampicin and ethambutol in order with an interval. However after administering ethambutol, neutropenia developed, so we discontinued ethambutol again. He was cured with isoniazid, rifampicin, and pyrazinamide for 9 months.
A 79-year-old man was referred to our hospital for fever and skin rash showed no further improvement with antipyretic drug and fluid therapy on 3 weeks after taking antituberculosis drugs (isoniazid, rifampicin, ethambutol, and pyrazinamide) at other hospital. Three weeks ago, he was diagnosed with pulmonary tuberculosis by positive acid-fast bacilli. Complete blood count (CBC) at the time of diagnosis of pulmonary tuberculosis was white blood cell (WBC) of 6.70×10
Introduction
Antituberculosis drugs may induce hematologic side effects such as thrombocytopenia and neutropenia, but agranulocytosis has rarely been reported. We describe a patient who developed agranulocytosis induced by ethambutol.
However, we stopped ethambutol due to fever and skin rash arised after adding ethambutol. There were no adverse effects of isoniazid and pyrazinamide for several days, so we added rifampicin and added ethambutol again with an interval. However, due to relapse of neutropenia (ANC of 1.43×10 3 /μL) in the sixth day after administrating ethambutol, we stopped ethambutol. And we continued isoniazid, rifampicin, and pyrazinamide for 9 months. He was cured without any other hematologic disorders.
Judging from the clinical course, we could conclude that ethambutol had caused agranulocytosis (Table 1) .
Discussion
Antituberculosis drugs have been shown to produce adverse effects from insignificance to life-threatening. In an immunocompetent patient, neutropenia is rare adverse effects of antituberculosis therapy. However, neutropenia combined with sepsis could lead to life-threatening. Umeki 1 reported that the incidence rate of neutropenia and agranulocytosis due to antituberculosis drugs were observed in 10.9% and 3.96%, respectively. Shishido et al. 2 reported that the incidence rate of 11,520 www.e-trd.org agranulocytosis due to antituberculosis drugs was estimated at 0.06%. Therefore, it is important to detect neutropenia earlier and treat it in a patient taking antituberculosis drugs. The causes of agranulocytosis mentioned above 1,2 were not ethambutol, but rifampicin and isoniazid. The important adverse effects of ethambutol are visual disturbance due to retrobulbar neuritis and toxicities to peripheral nerves 3, 4 . There is no well-documented report of agranulocytosis induced by ethambutol. Though Wong and Yew 5 suggested an association of neutropenia (ANC of 1.4×10 3 /μL) with ethambutol, but it was not agranulocytosis, but mild neutropenia.
Our case is the first report of agranulocytosis induced by ethambutol. According to the previous reports 1, 2, 6, 7 , neutropenia can be developed in a patient who is treated with antituberculosis drugs during a few months after starting administration. In administrating antituberculosis drugs including ethambutol, as in our case, we should regularly make a close monitoring of the CBC to avoid serious events.
